The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus

Lupus

Volumn 13, Issue 12, 2004, Pages 961-968

  Siripaitoon, Boonjing ^a,c   Osiri, M ^b   Vongthavaravat, V ^b   Akkasilpa, S ^b   Deesomchok, U ^b  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Antimalarial drugs; Dyslipoproteinemia; Premature atherosclerosis; Systemic lupus erythematosus (SLE)

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CHOLESTEROL; CYCLOPHOSPHAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DYSLIPOPROTEINEMIA; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MEXICO; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THAILAND;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; HYPOLIPOPROTEINEMIAS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THAILAND; TRIGLYCERIDES;

EID: 10844283575     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu1084xx     Document Type: Article

References (39)

1. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
2. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-519.
3. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987; 14(Suppl 13): 223-226.
4. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989; 68: 141-150.
5. Manzi S, Meilahn EN, Raine JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415.
6. Svenungsson E, Jensen-Urstad K, Heimburger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-1893.
7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
8. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of the low density lipoprotein cholesterol without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 502.
9. Tanphaichitr V, Pakpeankitvatana R, Viruenchavee N, Lochaya S, Watthana-kasetr S, Tamwiwat C. Serum lipid levels in participants of the cardiovascular electricity generating authority of Thailand (CEGAT) study. Intern Med 1999; 15: 107-112.
10. Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-1558.
11. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the systemic lupus international collaborating clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-813.
12. Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137-2143.
13. Lohsoonthorn V. BMI and health risks of health checkup clients at the preventive medicine clinic, King Chulalongkorn Memorial hospital. J Med Assoc Thai 2001; 84(Suppl 1): S269-S275.
14. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1566-1574.
15. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001; 10: 359-363.
16. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987; 83: 503-508.
17. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533-539.
18. Gotto AM. Lipid management in diabetic patients: lessons from prevention trials. Am J Med 2002; 112(Suppl 8A): 19S-26S.
19. Delgado AJ, Ames PR, Donohue S et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-2694.
20. Rader DJ. High-density lipoproteins and atherosclerosis. Am J Cardiol 2002; 90: 62i-70i.
21. Wamala SP, Wolk A, Schenck-Gustafsson K, Orth-Gomer K. Lipid profile and socioeconomic status in healthy middle aged women in Sweden. J Epidemiol Community Health 1997; 51: 400-407.
22. Wamala SP, Lynch J, Horsten M, Mittleman MA, Schenck-Gustafsson K, Orth-Gomer K. Education and the metabolic syndrome in women. Diabetes Care 1999; 22: 1999-2003.
23. Verschuren WM, Boerma GJ, Kromhout D. Total and HDL-cholesterol in The Netherlands: 1987-1992. Levels and changes over time in relation to age, gender and educational level. Int J Epidemiol 1994; 23: 948-956.
24. Hoeymans N, Smit HA, Verkleij H, Kromhout D. Cardiovascular risk factors in relation to educational level in 36 000 men and women in The Netherlands. Eur Heart J 1996; 17: 518-525.
25. Katzmarzyk PT, Leon AS, Rankinen T et al. Changes in blood lipids consequent to aerobic exercise training related to changes' in body fatness and aerobic fitness. Metabolism 2001; 50: 841-848.
26. Graziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96: 2520-2525.
27. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219.
28. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988; 31: 859-863.
29. Tengku-Muhammad TS, Cryer A, Ramji DP. Synergism between interferon gamma and tumour necrosis factor alpha in the regulation of lipoprotein lipase in the macrophage J774.2 cell line. Cytokine 1998; 10: 38-48.
30. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2957-2963.
31. Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metabolism 1984; 33: 521-526.
32. Donahoo WT, Kosmiski LA, Eckel RH. Drugs causing dyslipoproteinemia. Endocrinol Metah Clin North Am 1998; 27: 677-697.
33. Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28: 780-785.
34. Hodis HN, Quismorio FP Jr, Wickham E, Blankenhorn DH. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 661-665.
35. Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997; 3: 3-8.
36. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 254-259.
37. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26: 325-330.
38. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: 2142-2145.
39. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-326.